Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Luft

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Blood Cancer Journal|September 27, 2022
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMTKavita Raj, Dirk-Jan Eikema, Vipul Sheth, et al.
American Journal of Hematology|November 28, 2024
Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMTThomas Luft, Luuk Gras, Linda Koster, et al.
Blood Advances|March 25, 2026
Real-world experience with Tabelecleucel within and beyond the approval labelKiavasch Mohammad Nejad Farid, Florian Kocher, Tobias Arnold, et al.
Journal for Immunotherapy of Cancer|October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myelomaJan H Frenking, Xiang Zhou, Vivien Wagner, et al.
Blood|June 23, 2018
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associationsAndrea Pellagatti, Richard N Armstrong, Violetta Steeples, et al.
Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Bone Marrow Transplantation|September 10, 2025
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working PartyAgnieszka Piekarska, Mouad Abouqateb, William Boreland, et al.
Blood|July 15, 2024
Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)Katja Sockel, Annika Neu, Maren Goeckenjan, et al.
The Lancet. Haematology|October 14, 2019
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trialDietrich Wilhelm Beelen, Rudolf Trenschel, Matthias Stelljes, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Blood Cancer Journal|September 27, 2022
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMTKavita Raj, Dirk-Jan Eikema, Vipul Sheth, et al.
American Journal of Hematology|November 28, 2024
Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMTThomas Luft, Luuk Gras, Linda Koster, et al.
Blood Advances|March 25, 2026
Real-world experience with Tabelecleucel within and beyond the approval labelKiavasch Mohammad Nejad Farid, Florian Kocher, Tobias Arnold, et al.
Journal for Immunotherapy of Cancer|October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myelomaJan H Frenking, Xiang Zhou, Vivien Wagner, et al.
Blood|June 23, 2018
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associationsAndrea Pellagatti, Richard N Armstrong, Violetta Steeples, et al.
Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Bone Marrow Transplantation|September 10, 2025
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working PartyAgnieszka Piekarska, Mouad Abouqateb, William Boreland, et al.
Blood|July 15, 2024
Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)Katja Sockel, Annika Neu, Maren Goeckenjan, et al.
The Lancet. Haematology|October 14, 2019
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trialDietrich Wilhelm Beelen, Rudolf Trenschel, Matthias Stelljes, et al.
Pageof 12